A team of researchers at Georgia Tech is revolutionizing drug delivery by developing a method to administer injectable medications via pill form. This innovative approach could transform the way drugs like insulin and GLP-1s (such as Wegovy and Ozempic) are taken, potentially offering a more convenient and cost-effective alternative to traditional subcutaneous injections. Led by Mark Prausnitz, PhD, a Regents Professor of Chemical and Biomolecular Engineering, the research team has made significant strides in creating a pill that can deliver medications directly into the bloodstream through a unique chemical reaction.
The inspiration for this groundbreaking research stemmed from a fellowship received by a recent PhD candidate, Joshua Palacios, from the National Science Foundation. This opportunity allowed the team to explore new avenues in drug delivery technology, leading to the development of a pill-based delivery system. By using insulin as a model drug due to its widespread use and established analysis methods, the researchers demonstrated the potential for this pill to be adaptable for delivering a variety of medications beyond insulin, including GLP-1s. The pill functions by generating bubbles and pressure upon ingestion, causing the medication to burst through the shell and enter the bloodstream effectively.
The implications of delivering injectable drugs via pill form are vast, offering numerous advantages such as increased accessibility, affordability, and improved patient experience. For individuals like diabetics who require regular injections, transitioning to a pill-based delivery system could eliminate the need for frequent injections or clinic visits, streamlining the medication process and enhancing overall treatment adherence. Prausnitz envisions a future where this technology could benefit a wide range of patients by simplifying drug administration and improving therapeutic outcomes.
While the pill is still in the developmental stages and not yet available for commercial use, the successful proof-of-concept has paved the way for further research and optimization. The team’s next steps involve conducting additional studies to refine the technology before progressing to human trials. Prausnitz remains optimistic about the future of this innovation, aiming to advance towards a first-in-human study in the coming years pending adequate funding and research progress. This milestone represents a significant advancement in drug delivery technology and underscores the potential for pill-based administration to revolutionize patient care.
Notably, Prausnitz’s research portfolio extends beyond pill-based drug delivery, with a focus on developing innovative solutions such as microneedles for drug administration. His pioneering work in microneedle technology has led to advancements in vaccine delivery, including a clinical trial for a microneedle patch for measles and rubella vaccination. By exploring novel approaches to drug delivery, Prausnitz aims to address existing challenges in healthcare delivery and enhance patient access to essential medications. The versatility and impact of his research underscore the transformative potential of innovative drug delivery systems in improving public health outcomes.
- The development of injectable drugs in pill form by Georgia Tech researchers offers a promising alternative to traditional injections, with the potential to enhance patient adherence and treatment outcomes.
- By utilizing a unique chemical reaction to deliver medications, this technology could revolutionize drug administration for a wide range of conditions, providing a more accessible and cost-effective treatment option.
- The successful proof-of-concept for the pill-based delivery system represents a significant milestone in drug delivery technology, paving the way for further research, optimization, and eventual human trials.
- Prausnitz’s broader research efforts in microneedle technology demonstrate a commitment to advancing innovative drug delivery solutions and improving healthcare delivery for diverse patient populations.
Tags: drug delivery
Read more on atlantamagazine.com